Antiestrogen Therapy Increases Plasticity and Cancer Stemness of Prolactin-Induced ERα⁺ Mammary Carcinomas.

ABSTRACT: Although antiestrogen therapies are successful in many patients with estrogen receptor alpha-positive (ERα⁺) breast cancer, 25% to 40% fail to respond. Although multiple mechanisms underlie evasion of these treatments, including tumor heterogeneity and drug-resistant cancer stem cells (CSC), further investigations have been limited by the paucity of preclinical ERα⁺ tumor models. Here, we examined a mouse model of prolactin-induced aggressive ERα⁺ breast cancer, which mimics the epidemiologic link between prolactin exposure and increased risk for metastatic ERα⁺ tumors. Like a subset of ERα⁺ patient cancers, the prolactin-induced adenocarcinomas contained two major tumor subpopulations that expressed markers of normal luminal and basal

SUBMITTER: Shea MP 

PROVIDER: S-EPMC5882549 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature